Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms

Phase 2

Terminated

Interventions: Drug: Sarizotan low dose
Drug: Sarizotan high dose
Drug: Placebo

Brief Summary: This study evaluates the safety, tolerability and efficacy of Sarizotan in reducing respiratory abnormalities in Rett Syndrome in an initial double blind 24 week period followed by an open label treatment phase of up to 168 weeks (the latter for patients with no safety and tolerability issues).

Detailed Description: This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with respiratory abnormalities. The study participants will be randomized to either sarizotan between 2 and 10 mg bid or placebo bid, based on age and weight criteria.

All patients who have completed the final evaluations at Week 24 (Day 168) and have no safety or tolerability issues that would preclude continuing on the study medication and have been compliant with the trial requirements will have the option of continuing open-label treatment with Sarizotan for up to 168 weeks.

Recruitment & Eligibility

Inclusion Criteria

Body weight ≥ 10 kg
Age ≥ 4 years
Diagnosis of Rett syndrome based on consensus clinical criteria and patients with MECP2 duplications will not be eligible.
Has at least 10 episodes of breathing dysrhythmia, defined by episodes ≥10 seconds of breath holding (apnea), per hour during cardiorespiratory monitoring
Ability to take study medication provided either as capsules or combined with food/drink.
Patient is cooperative, willing to complete all aspects of the study, and capable of doing so with assistance of a caregiver.

Exclusion Criteria

Meets any of the diagnostic exclusion criteria for Rett syndrome, Typical (Neul et al, 2010);
Patient is participating in a clinical trial with another investigational drug
Hypersensitivity to sarizotan or other 5-HT1a agonists;
Current clinically significant (as determined by Investigator) cardiovascular, respiratory (e.g. severe asthma), gastrointestinal, renal, hepatic, hematologic or other medical disorders, in addition to those directly related to the patient's Rett syndrome;
QTcF interval on the ECG is greater than 450 msec.
Surgery planned during the study (except for insertion of gastrostomy tube);
Severe diabetes mellitus or fatty acid oxidation disorder.
Ophthalmologic history including any of the following conditions: albino patients, family history of hereditary retinal disease, retinitis pigmentosa, any active retinopathy or severe diabetic retinopathy.
Females who are pregnant, breastfeeding, or of childbearing potential and not using a hormonal contraceptive.

Arm && Interventions

Group	Intervention	Description
Sarizotan low dose	Sarizotan low dose	2 mg or 5 mg bid based on age and weight criteria for 24 wks DB 2 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 5 mg bid (≥13 years of age and weighing ≥25 kg)
Sarizotan high dose	Sarizotan high dose	5 mg or 10 mg bid based on age and weight criteria for 24 wks DB 5 mg bid (4 to \<13 years; ≥13 years of age and weighing \<25 kg 10 mg bid (≥13 years of age and weighing ≥25 kg)
Placebo	Placebo	Placebo bid for 24 wks DB age 4 and above

Primary Outcome Measures

Name	Time	Method
Reduction in Respiratory Abnormality in Patients With Rett Syndrome	Baseline up to week 24	Measured as the percent change in the number of apnea episodes per hour during awake time, calculated using an ambulatory data acquisition system (BioRadioTM) as part of home monitoring procedure. BioRadioTM record specific respiratory and cardiac parameters.

Secondary Outcome Measures

Name	Time	Method
Efficacy of Sarizotan Assessed by the Caregiver-rated Impression of Change	24 weeks	Caregiver-rated Impression of Change (CIC): 7-point scale requiring the caregiver to rate how much the patient's illness has improved or worsened relative to the baseline state. 7-point Likert-type scale for which ratings range from 1 = very much improved to 7 = very much worse, with 4 = no change. This caregiver-rated measure considered activities, behavior, mood and functioning. This rating was performed in consultation with the study Investigator but was based largely on the caregivers' evaluation during the reporting period. The single rating of the CIC was to be based on changes in the following domains: • Activities (watching TV, interest in conversations around her, cooperation during toileting, dressing/bathing, etc.), • Communication (verbal or by eye movements, hand movements, or head movements), • Behavior (agitation, refusal to feed, scratching, social avoidance), • Participation in family/outdoor/social events)

Locations (14): University of Alabama
🇺🇸
Birmingham, Alabama, United States
U.O. Neuropsichiatria Infantile
🇮🇹
Milano, Italy
South Metropolitan Health Service Fiona Stanley Hospital
🇦🇺
Murdoch, Western Australia, Australia
P.D. Hinduja National Hospital and Medical Research Centre
🇮🇳
Mumbai, India
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Baylor College of Medicine
🇺🇸
Houston, Texas, United States
Amrita Institute of Medical Sciences
🇮🇳
Kochi, Kerala, India
Vijaya Health Centre
🇮🇳
Chennai, Tamilnadu, India
Jaslok Hospital and Research centre
🇮🇳
Mumbai, India
All India Institute of Medical Sciences
🇮🇳
New Delhi, India
King's College Hospital
🇬🇧
London, United Kingdom
University of California
🇺🇸
San Diego, California, United States
A.O.U. Senese Policlinico Santa Maria alle Scotte
🇮🇹
Siena, Tuscany, Italy
Gillette Children's Specialty Healthcare
🇺🇸
Saint Paul, Minnesota, United States